Piramal's involvement with rimegepant's active pharmaceutical ingredient (API) relates to its role as a manufacturer for Biohaven Pharmaceuticals [1]. Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO) that produces the rimegepant API for Nurtec ODT, a medication used to treat migraines [1][2].
What is rimegepant?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [2]. It is approved for the acute treatment of migraine with or without aura and for the preventive treatment of episodic migraine [2].
How does Piramal manufacture rimegepant API?
Piramal Pharma Solutions utilizes its expertise in complex chemistry and large-scale manufacturing to produce the rimegepant API [1]. Their facilities are equipped to handle the intricate synthesis required for such molecules, ensuring quality and supply for Biohaven's medication [1][3].
When does rimegepant's patent protection expire?
Patent protection for rimegepant and its associated formulations is a critical factor for market exclusivity. DrugPatentWatch.com tracks these patents, which are essential for understanding the timeline for potential generic competition [4]. Specific patent expiry dates can vary based on different patents covering the compound, its synthesis, and its uses [4].
What are the commercial implications of Piramal's role?
As a CDMO, Piramal plays a vital role in the supply chain for rimegepant. Their ability to reliably produce the API supports Biohaven's commercialization efforts and ensures patient access to the migraine treatment [1][2]. Piramal's manufacturing capabilities can influence the cost and availability of the drug once patent protections expire and generic versions become available [4].